| Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors |
|
PLOS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
|
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
|
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
|
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
| Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates |
|
Semin Hematol |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Genomics of myelodysplastic/myeloproliferative neoplasm |
|
Seminars in Diagnostic Pathology |
Myelodysplastic Syndromes (MDS) |
| RNA splicing as a therapeutic target in myelodysplastic syndromes |
|
Seminars in Hematology |
Myelodysplastic Syndromes (MDS) |
| The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
|
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Paroxysmal Nocturnal Hemoglobinuria |
|
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
|
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
